316 related articles for article (PubMed ID: 21983283)
1. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
[TBL] [Abstract][Full Text] [Related]
2. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
3. Surface-modified LPD nanoparticles for tumor targeting.
Li SD; Huang L
Ann N Y Acad Sci; 2006 Oct; 1082():1-8. PubMed ID: 17145918
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
5. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
6. SAINT-liposome-polycation particles, a new carrier for improved delivery of siRNAs to inflamed endothelial cells.
Kowalski PS; Kuninty PR; Bijlsma KT; Stuart MC; Leus NG; Ruiters MH; Molema G; Kamps JA
Eur J Pharm Biopharm; 2015 Jan; 89():40-7. PubMed ID: 25460585
[TBL] [Abstract][Full Text] [Related]
7. Anginex lipoplexes for delivery of anti-angiogenic siRNA.
Yousefi A; Bourajjaj M; Babae N; Noort PI; Schaapveld RQ; Beijnum JR; Griffioen AW; Storm G; Schiffelers RM; Mastrobattista E
Int J Pharm; 2014 Sep; 472(1-2):175-84. PubMed ID: 24950365
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
9. Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells.
Adrian JE; Morselt HW; Süss R; Barnert S; Kok JW; Asgeirsdóttir SA; Ruiters MH; Molema G; Kamps JA
J Control Release; 2010 Jun; 144(3):341-9. PubMed ID: 20226822
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling.
Kou R; SenBanerjee S; Jain MK; Michel T
Biochemistry; 2005 Nov; 44(45):15064-73. PubMed ID: 16274253
[TBL] [Abstract][Full Text] [Related]
11. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.
Gao J; Yu Y; Zhang Y; Song J; Chen H; Li W; Qian W; Deng L; Kou G; Chen J; Guo Y
Biomaterials; 2012 Jan; 33(1):270-82. PubMed ID: 21963149
[TBL] [Abstract][Full Text] [Related]
12. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
14. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.
Gao J; Liu W; Xia Y; Li W; Sun J; Chen H; Li B; Zhang D; Qian W; Meng Y; Deng L; Wang H; Chen J; Guo Y
Biomaterials; 2011 May; 32(13):3459-70. PubMed ID: 21296406
[TBL] [Abstract][Full Text] [Related]
15. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma.
Jia RB; Zhang P; Zhou YX; Song X; Liu HY; Wang LZ; Luo M; Lu J; Ge SF; Fan XQ
Ophthalmic Res; 2007; 39(2):108-15. PubMed ID: 17284938
[TBL] [Abstract][Full Text] [Related]
16. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
17. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
Reich SJ; Fosnot J; Kuroki A; Tang W; Yang X; Maguire AM; Bennett J; Tolentino MJ
Mol Vis; 2003 May; 9():210-6. PubMed ID: 12789138
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of optimized liposomes for delivery of small interfering RNA.
Yang T; Bantegui T; Pike K; Bloom R; Phipps R; Bai S
J Liposome Res; 2014 Dec; 24(4):270-9. PubMed ID: 24708056
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of VEGF expression in A431 and MDA-MB-231 tumour cells by cationic lipid-mediated siRNA delivery.
Briane D; Slimani H; Tagounits A; Naejus R; Haddad O; Coudert R; Charnaux N; Cao A
J Drug Target; 2012 May; 20(4):347-54. PubMed ID: 22475204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
